Sandoz Aims For $6bn Biosimilar Business By 2030
Sandoz Has A 22% Share Of Global Biosimilars Market At Present
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
You may also be interested in...
Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review
Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.
Novartis Weighs Synergies, Spending And Tax Under Sandoz Review
Novartis gave further color during its Q3 earnings call on its plans to conduct a strategic review for its Sandoz business. The Street also had its say, following years of calls by investors for Novartis to weigh Sandoz’ future as part of the group.
$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options
Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.